Breaking News on Drug Discovery |
|
Format - Link
|
CHIRAL TECHNOLOGIES EUROPE announce the launch of CHIRALPAK® IC. The combination of CHIRALPAK® IA , IB and now IC provides a screening set of columns with exceptionally high success rates. The chiral separation of > 99% of all small molecules is attained using just 3 columns and four mobile phase combinations. |
18-Jun-2008 - In-PharmaTechnologist.com presents a digest of recent developments in the world of pharmaceutical ingredients, with news involving Evonik, BASF, Qiqihar No. 2 Pharmaceutical Co and Shengtai Pharmaceutical.
30-Apr-2008 - India's Dr Reddy's Laboratories has just announced the signing of a definitive agreement to buy the US pharmaceutical contract manufacturing business of chemicals giant BASF.
10-Apr-2008 - Actavis has purchased a 90 per cent stake in Zhejiang Chiral Medicine Chemicals (CMC), a Hangzhou, China-based active pharmaceutical ingredients (API) maker.
03-Apr-2008 - Three of India´s large pharmaceutical manufacturers, Dr Reddy's, Ranbaxy Laboratories and Shilpa Medicare have just announced new merger and acquisition (M&A) deals.
11-Jun-2007 - A new technique could result in better nutritional and safety profiles for the coming generation of genetically modified organisms (GMOs), Spanish scientists have reported.
21-Feb-2007 - Pharmaceutical services group Almac Sciences has teamed up with enzyme catalyst firm BioCatalytics on process development and manufacture of chiral intermediates and active pharmaceutical ingredients (APIs).
19-Feb-2007 - Excelsyn and SAFC Both announced improvements to their UK contract manufacturing operations at this year's pharma services and specialty chemicals trade show, InformexUSA, in San Francisco.
16-Feb-2007 - A round up of recent product releases from across the industry.
18-Dec-2006 - Solvay has contracted Novasep to provide synthesis of two active pharmaceutical ingredients, following Novasep's decision to combine synthesis and processing expertise.
21-Nov-2006 - Sigma-Aldrich (SAFC) will soon offer new solid-form research capabilities at its US high-potency active pharmaceutical ingredients (API) facility in Madison, Wisconsin.